4.7 Article

Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease

期刊

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2010.884

关键词

-

资金

  1. Abbott Laboratories
  2. National Heart, Lung, and Blood Institute (NHLBI)
  3. Fujisawa
  4. Pfizer
  5. GlaxoSmithKline
  6. Vascular Biology Working Group (AstraZeneca, Sanofi Aventis, Schering-Plough, Daiichi Sankyo Lilly, AtCor Medical, XOMA)
  7. Juvenile Diabetes Research Foundation
  8. Forest Laboratories
  9. CVRx
  10. Merck
  11. Novartis
  12. Boehringer-Ingelheim
  13. Takeda
  14. Walgreens
  15. Bristol Meyer Squibb/Sanofi
  16. Gilead
  17. Forest Labs
  18. Fibrogen
  19. Spherix
  20. Johnson Johnson
  21. Daiichi Sankyo
  22. Bioheart Inc
  23. AstraZeneca
  24. AtCor Medical Inc
  25. Daiichi Sankyo Inc
  26. Eli Lilly
  27. Pfizer Inc
  28. Sanofi-Aventis
  29. Schering-Plough
  30. University of Florida
  31. National Institutes of Health [K23HL086558, UOIGM074492]

向作者/读者索取更多资源

Context Hypertension guidelines advocate treating systolic blood pressure (BP) to less than 130 mm Hg for patients with diabetes mellitus; however, data are lacking for the growing population who also have coronary artery disease (CAD). Objective To determine the association of systolic BP control achieved and adverse cardiovascular outcomes in a cohort of patients with diabetes and CAD. Design, Setting, and Patients Observational subgroup analysis of 6400 of the 22 576 participants in the International Verapamil SR-Trandolapril Study (INVEST). For this analysis, participants were at least 50 years old and had diabetes and CAD. Participants were recruited between September 1997 and December 2000 from 862 sites in 14 countries and were followed up through March 2003 with an extended follow-up through August 2008 through the National Death Index for US participants. Intervention Patients received first-line treatment of either a calcium antagonist or beta-blocker followed by angiotensin-converting enzyme inhibitor, a diuretic, or both to achieve systolic BP of less than 130 and diastolic BP of less than 85 mm Hg. Patients were categorized as having tight control if they could maintain their systolic BP at less than 130 mm Hg; usual control if it ranged from 130 mm Hg to less than 140 mm Hg; and uncontrolled if it was 140 mm Hg or higher. Main Outcome Measures Adverse cardiovascular outcomes, including the primary outcomes which was the first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Results During 16 893 patient-years of follow-up, 286 patients (12.7%) who maintained tight control, 249 (12.6%) who had usual control, and 431 (19.8%) who had uncontrolled systolic BP experienced a primary outcome event. Patients in the usual-control group had a cardiovascular event rate of 12.6% vs a 19.8% event rate for those in the uncontrolled group (adjusted hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.25-1.71; P<.001). However, little difference existed between those with usual control and those with tight control. Their respective event rates were 12.6% vs 12.7% (adjusted HR, 1.11; 95% CI, 0.93-1.32; P=.24). The all-cause mortality rate was 11.0% in the tight-control group vs 10.2% in the usual-control group (adjusted HR, 1.20; 95% CI, 0.99-1.45; P=.06); however, when extended follow-up was included, risk of all-cause mortality was 22.8% in the tight control vs 21.8% in the usual control group (adjusted HR, 1.15; 95% CI, 1.01-1.32; P=.04). Conclusion Tight control of systolic BP among patients with diabetes and CAD was not associated with improved cardiovascular outcomes compared with usual control.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据